Nephrogenic systemic fibrosis: A serious adverse reaction to gadolinium-1997-2006-2016. Part 1

Acta Radiologica

Volumn 57, Issue 5, 2016, Pages 515-520

  Thomsen, Henrik S ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIC ACID; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; CONTRAST MEDIUM;

CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TISSUE LEVEL; HUMAN; INTERMETHOD COMPARISON; LD50; MICROSCOPY; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SKIN BIOPSY; SKIN INDURATION; WALKING DIFFICULTY; ANIMAL; CHEMICALLY INDUCED;

ANIMALS; CONTRAST MEDIA; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY;

EID: 84978731548     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1177/0284185115626480     Document Type: Review

References (41)

1. Thomsen HS, Reimer P. Intravascular contrast media for radiography, CT, MRI and ultrasound (chap. 2). In: Adam A, Dixon AK, Gillard JH, et al. (eds) Grainger & Allison's Diagnostic Radiology-a textbook of medical imaging. Edinburgh: Churchill Livingstone Elsevier, 2015, pp. 26-51.
2. Thomsen HS, Bongartz GM. Acute adverse reactions to gadolinium-based contrast media. In: Thomsen HS, Webb JAW (eds) Contrast Media: Safety Issues and ESUR Guidelines, 3rd ed. Heidelberg: Springer, 2014, pp. 201-206.
3. Thomsen HS, Leander P. Radiography with gadoliniumbased contrast media. In: Thomsen HS, Webb JAW (eds) Contrast Media: Safety Issues and ESUR Guidelines, 3rd ed. Heidelberg: Springer, 2014, pp. 193-200.
4. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104e8.
5. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359-2362.
6. Thomsen HS. NSF: Still relevant. JMRI J Mag Reson Imag 2014;40:11-12.
7. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous disease in renal dialysis patients. Lancet 2000;356:1000-1001.
8. Girardi M, Kay J, Elston DM. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 2011;65:1095-1106.
9. Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol 2008;66:200-207.
10. Thomsen HS, Marckmann P, Logager VB. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imag 2007; 7:130-137.
11. Marckmann P, Skov L, Rossen K, et al. Clinical manifestations of gadodiamide-related nephrogenic systemic fibrosis. Clin Nephrol 2008;69:161-168.
12. Todd DJ, Kagan A, Chibnik LB, et al. Cutaneous changes of nephrogenic systemic fibrosis. Predictor of early mortality and association with gadolinium exposure. Arthritis Rheumat 2007;56:3433-3441.
13. Swaminathan S, High WA, Ranville J, et al. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int 2008;73:1413-1418.
14. De Haen C. Conception of the first magnetic resonance imaging contrast agents: a brief history. Top Magn Reson Imaging 2001;12:221-230.
15. Weinmann H-J, Brasch R, Press W-R, et al. Characteristics of gadolinium-DTPA complex: A potential NMR contrast agent. Am J Roentgenol 1984;142: 619-624.
16. Evans CH, Drouven BJ. The promotion of collagen polymerization by lanthanide and calcium ions. Biochem J 1983;213:751-758.
17. Evans CH. Biochemistry of the lanthanides. New York, NY: Plenum Press, 1990.
18. SMRM workshop on contrast enhanced magnetic resonance. Discussion. Magn Reson Med. 1991;22:229-232.
19. Müller N, Günzel P, Schöbel C. Ionic and non-ionic gadolinium-containing magnetic resonance contrast media. Comparison of effects and their reversibility in repeated dose toxicity studies in rats. Advances in MRI Contrast 1992;1(Suppl. 1):15-28.
20. Maton F, van der Elst L, Muller RN. Influence of human proteins on the relaxivity of Gd(III) complexes. 1995. Available at: http://www. b. dk/upload/webred/bmsandbox/ uploads/2012/03/bb81a28663015b7a1d828ee723-de7a26. pdf (accessed 4 June 2012).
21. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium based magnetic resonance imaging contrast agents in human serum at 37C. Invest Radiol 2008;43: 817-828.
22. Prince MR, Erel HE, Lent RW, et al. Gadodiamide administration causes spurious hypocalcemia. Radiology 2003;227:639-646.
23. Morcos SK. Contrast media and interactions with other drugs and clinical tests. In: Thomsen HS, Webb JAW (eds) Contrast Media: Safety Issues and ESUR Guidelines, 3rd ed. Heidelberg: Springer, 2014, pp. 121-130.
24. Proctor KAS, Rao LV, Roberts WL. Gadolinium magnetic resonance contrast agents produce analytic interference in multiple serum assays. Am J Clin Pathol 2004; 121:282-292.
25. Choyke PL, Knopp MV. Pseudohypocalcemia with MR imaging contrast agents: a cautionary tale. Radiology 2003;227:627-628.
26. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 2007;80:73-76.
27. Rosky NM, Sherry AD, Lenkinski RE. Nephrogenic systemic fibrosis: A chemical perspective. Radiology 2008; 247:608-612.
28. Morcos SK. Gadolinium chelates and stability. In: Thomsen HS, Webb JAW (eds) Contrast Media: Safety Issues and ESUR Guidelines, 3rd ed. Heidelberg: Springer, 2014, pp. 175-180.
29. Morcos SK, Thomsen HS, Webb JAW. Contrast Media Safety Committee of the European Society of Urogenital Radiology (ESUR) Dialysis and contrast media. Eur Radiol 2002;12:3026-3030.
30. Parazella MA. Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? Clin J Am Soc Nephrol 2007;2:200-202.
31. Thomsen HS. Nephrogenic systemic fibrosis and gadolinium-based contrast media. In: Thomsen HS, Webb JAW (eds) Contrast Media: Safety Issues and ESUR Guidelines, 3rd ed. Heidelberg: Springer, 2014, pp. 201-217.
32. Cowper SE. Nephrogenic systemic fibrosis. Adv Dermatol 2007;23:131-154.
33. Sieber MA, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium based contrast media. Invest Radiol 2008;43:65-75.
34. Sieber MA, Lengsfeld P, Walter J, et al. Gadolinium based contrast agents and their potential role in the patho-genesis of nephrogenic systemic fibrosis: the role of excess ligand. J Magn Reson Imaging 2008;27:955-962.
35. Watson AD, Rocklage SM, Carvlin MJ. Contrast agents (chap 14). In: Stark DD, Bradley WG (eds) Magnetic Resonance Imaging. St. Louis, MO: Mosby Year Book, 1992, pp. 372-437.
36. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 1995;30:372-380.
37. Wadas TJ, Sherman CD, Miner JH, et al. The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice. Magn Reson Med 2010;64:1274-1280.
38. White GW, Gibby WA, Tweedle MF. Comparison of Gd (DTPA-BMA) (Omniscan) versus GD (HP-DO3A) (Prohance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006;41:272-278.
39. Edward M, Quinn JA, Mukherjee S. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 2008;214:584-593.
40. MacNeil S, Bains S, Johnson C, et al. Gadolinium contrast agent associated stimulation of human fibroblast collagen production. Invest Radio 2011;46:711-717.
41. Haylor J, Schroeder J, Wagner B, et al. Skin gadolinium following MRI contrast agents in a rat model of nephrogenic systemic fibrosis. Radiology 2012;263:107-116.